An Act to amend and reenact §§ 4.1-1600, 4.1-1602, and 4.1-1603 of the Code of Virginia, relating to medical cannabis program; product labels; delivery.
HB391 amends Virginia’s medical cannabis laws by updating definitions in the medical cannabis program and by revising rules related to product labeling and delivery. The bill defines and clarifies several key terms used in the chapter, including “cannabis product,” “edible cannabis product,” “inhalable cannabis product,” “pharmaceutical processor,” “cannabis dispensing facility,” and a new “marijuana delivery operator.” It also specifies that marijuana delivery operators may take possession of certain cannabis products from a pharmaceutical processor or dispensing facility and deliver them in person to patients at their residence or business.
The bill continues to frame Virginia’s medical cannabis system around Board-permitted pharmaceutical processors and dispensing facilities, with products limited to registered, tested items containing no more than 10 milligrams of THC per dose unless otherwise provided in the chapter. It also refines the relationship between cannabis oil, botanical cannabis, and industrial hemp, and preserves the role of licensed medical practitioners in issuing written certifications for patient access. Overall, the measure appears to modernize and expand the operational details of the medical cannabis program rather than fundamentally change eligibility for medical use.
HB391 amends §§ 4.1-1600, 4.1-1602, and 4.1-1603 of the Code of Virginia, affecting the statutory framework governing medical cannabis in Virginia. Its main legal effect is to add and refine definitions and to authorize a regulated in-person delivery model for medical cannabis products through licensed marijuana delivery operators, while maintaining Board oversight of processors, dispensing facilities, product registration, and testing requirements. The bill affects pharmaceutical processors, cannabis dispensing facilities, licensed delivery operators, patients, registered agents, and certain caregivers and facilities that may receive or facilitate access to medical cannabis products.
The available legislative record shows no committee transcript or recorded vote data, so there is no direct evidence of debate or opposition in the provided materials. Based on the enacted chapter text, the bill appears to have been treated as a technical and operational update to the medical cannabis program, suggesting generally neutral to favorable sentiment toward improving access and clarifying program administration. The fact that it was approved and enacted indicates sufficient support for the changes.
No specific points of contention are documented in the provided transcripts or votes. Potential areas that could have drawn scrutiny, based on the bill text, include the creation of marijuana delivery operators, the scope of in-person delivery to residences and businesses, and the continued regulatory distinction between medical cannabis, botanical cannabis, and industrial hemp. Any concerns would likely center on patient access, public safety, product control, and regulatory oversight, but those issues are not explicitly reflected in the supplied legislative history.